Siemens Healthineers MRI will help clinicians at Royal Brompton Hospital visualise the heart in greater details. Image credit: Shutterstock / nimon.

Inspire Medical Systems has secured the CE Mark certification of full-body MRI compatibility for its Inspire IV neurostimulator device under the European Union’s Medical Device Regulation (EU MDR).

This approval extends the use of Inspire therapy beyond the previously allowed head, neck, and extremity MRI scans.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The CE Mark approval retroactively applies to all patients implanted with the Inspire IV neurostimulator since 2018.

This advancement ensures that these patients can now safely undergo full-body MRI scans.

Inspire chairman and CEO Tim Herbert said: “Expanding compatible use to include full-body MRI is a significant milestone in our effort to bring Inspire to more obstructive sleep apnoea (OSA) patients who struggle with CPAP [continuous positive airway pressure]. Providing the full range of scan options enables us to better help all current and future patients with their imaging needs.

See Also:

“This full-body MRI compatibility has been an important benefit for patients in the United States for the past two years, and this new approval will provide the same positive benefit for patients in Europe going forward.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Inspire Medical Systems has conducted thorough testing to confirm that the Inspire IV neurostimulator can perform safely within a 1.5T MRI environment.

Inspire Europe managing director and executive vice-president Andreas Henke said: “Until now, concern over future access to MRI had been a barrier for some patients considering Inspire therapy.

“Compatibility with this important diagnostic tool will provide peace of mind for current and future Inspire patients.”

The therapy is said to be the first and only US Food and Drug Administration (FDA)-approved neurostimulation technology designed to provide a safe treatment for moderate to severe OSA.

The company is engaged in the development and commercialisation of minimally invasive solutions for OSA patients.